Case number 1:22-cv-00965
Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 30, 2023 | 19 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Stipulated Consent Judgment)(mdb) (Entered: 03/30/2023) (Main Document) (1) |
| Mar 30, 2023 | 19 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Stipulated Consent Judgment)(mdb) (Entered: 03/30/2023) (Stipulated Consent Judgment) (2) |
| Nov 18, 2022 | 18 | SO ORDERED re 17 Stipulation and Order Regarding Case Consolidation. Signed by Judge Maryellen Noreika on 11/18/2022. (dlw) (Entered: 11/18/2022) (3) |
| Nov 16, 2022 | 17 | STIPULATION Regarding Consolidation, Case Schedule, and Protective Order, by Neurocrine Biosciences, Inc.. (Balick, Steven) (Entered: 11/16/2022) (3) |
| Nov 10, 2022 | 16 | STIPULATION Seeking to Extend the Deadline by Which the Parties in the Non-Consolidated Cases Must Inform the Court Whether they Agree to be Consolidated With, and Adopt the Schedule of the Lead Case, by Neurocrine Biosciences, Inc.. (Balick, Steven) (Entered: 11/10/2022) (5) |
| Nov 1, 2022 | 14 | ANSWER to 1 Complaint, Affirmative Defenses, COUNTERCLAIM against Neurocrine Biosciences, Inc. by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc., Teva Pharmaceuticals Development, Inc. (Hoeschen, Nathan) Modified on 11/1/2022 (dlw). (Entered: 11/01/2022) (26) |
| Nov 1, 2022 | 15 | Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc. filed by Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 11/01/2022) (2) |
| Oct 31, 2022 | 13 | SO ORDERED re 12 Stipulation and Order Dismissing Defendant Teva Pharmaceutical Industries Ltd. without Prejudice and Amending Caption to Reflect Same. Party Teva Pharmaceutical Industries Ltd. terminated. Signed by Judge Maryellen Noreika on 10/31/2022. (dlw) (Entered: 10/31/2022) (5) |
| Oct 28, 2022 | 12 | STIPULATION of Dismissal Without Prejudice (Teva Pharmaceutical Industries Ltd.) and Order Amending Caption by Neurocrine Biosciences, Inc. (Balick, Steven) Modified on 10/31/2022 (dlw). (Entered: 10/28/2022) (5) |
| Oct 21, 2022 | 9 | WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Teva Pharmaceuticals, Inc. waiver sent on 10/12/2022, answer due 12/12/2022. (Balick, Steven) (Entered: 10/21/2022) (1) |
| Oct 21, 2022 | 10 | WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Teva Pharmaceuticals Development, Inc. waiver sent on 10/12/2022, answer due 12/12/2022. (Balick, Steven) (Entered: 10/21/2022) (1) |
| Oct 21, 2022 | 11 | WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Teva Pharmaceuticals USA, Inc. waiver sent on 10/12/2022, answer due 12/12/2022. (Balick, Steven) (Entered: 10/21/2022) (1) |
| Oct 19, 2022 | 8 | ORAL ORDER RESETTING Teleconference - IT IS HEREBY ORDERED that the 10/24/2022 teleconference is RESET for 11/3/2022 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 10/19/2022. (dlw) (Entered: 10/19/2022) (0) |
| Oct 14, 2022 | 7 | NOTICE OF SERVICE of Neurocrine Biosciences, Inc.'s First Set of Requests to Defendants for the Production of Documents and Things (Nos. 1-41) filed by Neurocrine Biosciences, Inc..(Mayo, Andrew) (Entered: 10/14/2022) (4) |
| Oct 6, 2022 | 6 | ORAL ORDER Setting Teleconference: IT IS HEREBY ORDERED that a Telephone Conference is set for 10/24/2022 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 10/6/2022. (dlw) (Entered: 10/06/2022) (0) |
| Jul 27, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) |
| Jul 22, 2022 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (mpb) |
| Jul 22, 2022 | 1 | Main Document (13) Docket Text: COMPLAINT filed against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals Development, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-3921162.) - filed by Neurocrine Biosciences, Inc.. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(mpb) |
| Jul 22, 2022 | 1 | Exhibit A (25) |
| Jul 22, 2022 | 1 | Civil Cover Sheet (3) |
| Jul 22, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) |
| Jul 22, 2022 | 3 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,311,532. (mpb) |
| Jul 22, 2022 | 4 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: June 10, 2022. Date of Expiration of Patent: September 18, 2038.Thirty Month Stay Deadline: 10/11/2024. (mpb) |
| Jul 22, 2022 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Neurocrine Biosciences, Inc.. (mpb) |
| Jul 22, 2022 | 1 | Complaint* (1) |
